Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G

被引：2
|
作者：
Sugimoto, Naotoshi
Sakai, Daisuke
Tamura, Takao
Hara, Hiroki
Nishina, Tomohiro
Esaki, Taito
Okuda, Hiroyuki
Denda, Tadamichi
Tsuda, Masahiro
Satoh, Taroh
Makiyama, Akitaka
Yamazaki, Kentaro
Kuramochi, Hidekazu
Hosokawa, Ayumu
Tsuda, Takashi
Taniguchi, Hiroya
Kishimoto, Junji
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
机构：
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Gastrointestinal Oncol, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[3] Kinki Univ, Osaka, Japan
[4] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[5] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Fukuoka, Japan
[7] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[8] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan
[9] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan
[10] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan
[11] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[12] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi, Chiba, Japan
[13] Toyama Univ, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan
[14] St Marianna Univ Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
[15] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[16] Kyushu Univ, Fukuoka, Fukuoka, Japan
[17] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[18] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan
[19] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Phase I-II study of irinotecan (CPT-11) and gefitinib in patients (pts) with gefitinib failure for non-small cell lung cancer (NSCLC)
    Horiike, A.
    Ohyanagi, F.
    Okano, Y.
    Kudo, K.
    Miyauchi, E.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients
    Okabayashi, Koji
    Hasegawa, Hirotoshi
    Ishii, Yoshiyuki
    Endo, Takashi
    Ochiai, Hiroki
    Kubota, Tetsuro
    Kitagawa, Yuko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 501 - 507
  • [34] Phase I/II study of 24-hour infusion of irinotecan (CPT-11) in combination with sequential oral leucovorin (LV) and uracil/tegafur (UFT) for patients (PTS) with metastatic colorectal cancer (MCRC)
    Sadahiro, Sotaro
    Maeda, Yuji
    Suzuki, Toshiyuki
    Makuuchi, Hiroyasu
    Kamijo, Akemi
    Murayama, Chieko
    ANNALS OF ONCOLOGY, 2006, 17 : 117 - 117
  • [35] Irinotecan (CPT-11) plus mitomycin C (MMC) for the second line treatment of patients (PTS) with advanced colorectal carcinoma (ACC). A phase I/II study.
    Casaretti, R
    Biglietto, M
    De Lucia, L
    De Cataldis, G
    Di Lullo, L
    Maiorino, L
    Avallone, A
    Guarrasi, R
    Comella, P
    Comella, G
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [36] PHASE I-II STUDY OF IRINOTECAN (CPT-11) AND GEFITINIB IN PATIENTS (PTS) WITH GEFITINIB FAILURE FOR NON-SMALL CELL LUNG CANCER (NSCLC)
    Horiike, A.
    Ohyanagi, F.
    Kudo, K.
    Miyauchi, E.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 108 - 108
  • [37] TIMED-FLAT-INFUSION (TFI) OF 5-FLUOROURACIL (5-FU) PLUS WEEKLY ALTERNATING IRINOTECAN (CPT-11) AND OXALIPLATIN (L-OHP) IN ADVANCED COLORECTAL CANCER: PRELIMINARY RESULTS OF A DOSE-FINDING STUDY
    Morelli, M. F.
    Ricevuto, E.
    Calista, F.
    Gugliemi, F.
    Cannita, K.
    Rispoli, A. I.
    Santomaggio, A.
    Porzio, G.
    Lanfiuti, P.
    Mancini, M.
    Marchetti, P.
    Ficorella, C.
    ANNALS OF ONCOLOGY, 2004, 15 : 64 - 64
  • [38] Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including oxaliplatin, irinotecan (CPT-11), and 5-fluorouracil (5-FU) or capecitabine
    Souglakos, J
    Androulakis, N
    Kalykaki, A
    Saridaki, Z
    Vardakis, N
    Kalbakis, K
    Agelaki, S
    Vamvakas, L
    Kentepozidis, N
    Giassas, S
    Mavroudis, D
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
  • [39] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
  • [40] A phase I/II study of tegafur-uracil (UFT) plus oral leucovorin (LV) and biweekly CPT-11 therapy for patients (pts) with metastatic colorectal cancer (CRC).
    Uetake, H
    Tetsuro, H
    Enomoto, M
    Sugihara, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
12345